"L'institut de Cancérologie de Bourgogne est un établissement de santé qui regroupe plusieurs centres dans le traitement du cancer à Dijon, Chalon-sur-Saône et Auxerre. Les centres de traitements à Dijon se situe dans les locaux de la Polyclinique du Parc-Drevon et de la clinique Bénigne Joly de Talant."

During the past decade, Institut de Cancérologie de Bourgogne conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut de Cancérologie de Bourgogne" #1 sponsor was "Federation Francophone de Cancerologie Digestive" with 7 trials, followed by "UNICANCER" with 3 trials sponsored, "ARCAGY/ GINECO GROUP" with 2 trials sponsored, "Centre Hospitalier Universitaire Dijon" with 1 trials sponsored and "Centre Hospitalier Universitaire de Besancon" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut de Cancérologie de Bourgogne" #1 collaborator was "National Cancer Institute, France" with 3 trials as a collaborator, "GERCOR - Multidisciplinary Oncology Cooperative Group" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Association de Neuro-Oncologues d'Expression Francaise" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Institut de Cancérologie de Bourgogne" are "Metastatic Colorectal Cancer" (3 trials), "Colorectal Neoplasms" (2 trials), "Metastatic Breast Cancer" (2 trials), "Advanced Renal Cell Carcinoma" (1 trials) and "Bone Metastases" (1 trials). Many other conditions were trialed in "Institut de Cancérologie de Bourgogne" in a lesser frequency.

Most popular intervention types in "Institut de Cancérologie de Bourgogne" are "Drug" (13 trials), "Radiation" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (4 trials), "Gemcitabine" (2 trials), "LV5FU2" (2 trials), "Panitumumab" (2 trials) and "5 FU bolus" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut de Cancérologie de Bourgogne" are 14 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Institut de Cancérologie de Bourgogne". undefined are not yet recruiting, 11 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Institut de Cancérologie de Bourgogne, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut de Cancérologie de Bourgogne, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".